An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

With ulcerative colitis (UC), it may feel like each day presents a new hurdle. You can get your symptoms under control and keep them in remission with treatment, yet because of the somewhat ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...

What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

You and your doctor already have a variety of treatment options available for ulcerative colitis (UC), but science marches on, with the pharmaceutical industry close behind. Dozens of novel therapies ...

Biologic therapy within a year of diagnosis could decrease risk for disease progression among patients with ulcerative ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

Spyre Therapeutics Inc. SYRE shares are up on Monday following the announcement of positive results from the Phase 2 SKYLINE ...

The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

U.S. Ulcerative Colitis Market is projected to grow from USD 3.22 Billion in 2025 to USD 4.94 Billion by 2035 Increasing Cases of Ulcerative Colitis in the U.S.Austin, April 16, 2026 (GLOBE NEWSWIRE) ...